Email this article 
Results of the two-year treatment with avonex of 34 patients with relapsing remitting multiple sclerosis are summarized. This study provides evidence for the significant decrease in activity of the pathological process in patients treated with avonex, which is confirmed by the reduction of the relapse rate and the increase of the
proportion of patients remaining exacerbation-free. The decrease of the EDSS score has also been shown. In general, avonex was tolerated well in patients under study.
Results of the study of avonex efficiency in multiple sclerosis
- Authors: Peresedova A.V.1, Stoida N.I.1, Askarova L.S.1, Zakharova M.N.1, Adarcheva L.S.2, Niyazbekova A.S.3, Trifonova O.V.1, Rebrova O.Y.3, Zavalishin I.A.1
-
Affiliations:
- Research Center of Neurology
- Research Center of Neurology, Russian Academy of Medical Sciences,
- Research Center of Neurology, Russian Academy of Medical Sciences
- Issue: Vol 4, No 3 (2010)
- Pages: 20-24
- Section: Original articles
- URL: https://annaly-nevrologii.com/journal/pathID/article/view/335
- DOI: https://doi.org/10.17816/psaic335
- ID: 335
Cite item
Full Text
Abstract
Keywords
About the authors
A. V. Peresedova
Research Center of Neurology
Author for correspondence.
Email: neuro_inf@neurology.ru
Russian Federation, Moscow
N. I. Stoida
Research Center of Neurology
Email: neuro_inf@neurology.ru
Russian Federation, Моscow
Lola Sh. Askarova
Research Center of Neurology
Email: neuro_inf@neurology.ru
Russian Federation, Moscow
Maria N. Zakharova
Research Center of Neurology
Email: neuro_inf@neurology.ru
Russian Federation, Moscow
L. S. Adarcheva
Research Center of Neurology, Russian Academy of Medical Sciences,
Email: neuro_inf@neurology.ru
Russian Federation, Moscow
A. S. Niyazbekova
Research Center of Neurology, Russian Academy of Medical Sciences
Email: neuro_inf@neurology.ru
Russian Federation, Moscow
Olga V. Trifonova
Research Center of Neurology
Email: neuro_inf@neurology.ru
Russian Federation, Moscow
O. Yu. Rebrova
Research Center of Neurology, Russian Academy of Medical Sciences
Email: neuro_inf@neurology.ru
Russian Federation, Moscow
I. A. Zavalishin
Research Center of Neurology
Email: neuro_inf@neurology.ru
Russian Federation, Moscow
References
- Bermel R.A., Weinstock-Guttman B., Bourdette D. et al. Intramuscular interferon beta-1a therapy in patients with relapsingremitting multiple sclerosis: a 15-year follow-up study. Mult. Scler. Online First, published on February 18, 2010.
- Betaseron Efficacy Yielding Outcomes of New Dose (BEYOND). Press Release, Bayer Healthcare AG, October 29, 2007.
- Boster A., Racke M.K. Pharmacotherapy of multiple sclerosis: the PROOF trial. Expert Opin. Pharmacother. 2009; 10: 1235–1237.
- Clanet M., Radue E.W., Kappos L. et al. A randomized, doubleblind dose comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002; 59: 1507–1517.
- Comi G. Induction vs. escalating therapy in multiple sclerosis: practical implications. Neurol. Sci. 2008; 29 (Suppl. 2): 253–255.
- Freedman S.M. Dose response to interferon therapy in multiple sclerosis: an evaluation of the evidence. Curr. Med. Res. Opin. 2009; 25: 547–557.
- PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon -1a in relapsing-remitting multiple sclerosis. Lancet 1998; 352: 1498–1504.
- Reynolds M.W., Stephen R., Seaman C., Rajagopalan K. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Curr. Med. Res. Opin. 2010; 26: 663–674.
- The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicentral, randomized double bind, placebo-controlled trial. Neurology 1993; 43: 655–661.
- Zidanov R., Locatelli L., Cookfair D. et al. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult. Scler. 2007; 13: 490–501.
- Zidanov R., Munschauer F.E., Ramanathan M. et al. Clinical efficacy, effects on MRI and tolerability of weekly intramuscular interferon-beta-1a in patients with MS and CIS. Drugs Today 2008; 44: 601–613.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).